BRIEF

on Carl Zeiss Meditec AG (ETR:AFX)

Carl Zeiss Meditec Reports Decline in Earnings and Revenue

Stock price chart of Carl Zeiss Meditec AG (EBR:AFX) showing fluctuations.

Carl Zeiss Meditec AG has disclosed lower earnings for the first half of the fiscal year 2025/26, with a decline in revenue from €1,050.5 million to €991.0 million, marking a 5.7% decrease. Adjusted EBITA also fell significantly to €60.5 million from €112.6 million. The company attributes this decline primarily to unfavorable currency effects and challenges in the intraocular lens business.

Regionally, the EMEA region showed stability, while the Americas and APAC regions experienced significant downturns, due in part to geopolitical uncertainties. Strategic business units for Ophthalmology and Microsurgery both underperformed compared to the previous year.

The management plans extensive measures to restore profitability, including structural and cost optimizations, expecting an earnings improvement of over €200 million annually by 2028/29. These adjustments will support future investment in growth and innovation.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Carl Zeiss Meditec AG news